fosfomycin and Obesity

fosfomycin has been researched along with Obesity* in 2 studies

Trials

1 trial(s) available for fosfomycin and Obesity

ArticleYear
Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial.
    The Journal of antimicrobial chemotherapy, 2019, 08-01, Volume: 74, Issue:8

    To assess the pharmacokinetics and tissue penetration of fosfomycin in obese and non-obese surgical patients.. Fifteen obese patients undergoing bariatric surgery and 15 non-obese patients undergoing major intra-abdominal surgery received an intravenous single short infusion of 8 g of fosfomycin. Fosfomycin concentrations were determined by LC-MS/MS in plasma and microdialysate from subcutaneous tissue up to 8 h after dosing. The pharmacokinetic analysis was performed in plasma and interstitial fluid (ISF) by non-compartmental methods.. Thirteen obese patients (BMI 38-50 kg/m2) and 14 non-obese patients (BMI 0-29 kg/m2) were evaluable. The pharmacokinetics of fosfomycin in obese versus non-obese patients were characterized by lower peak plasma concentrations (468 ± 139 versus 594 ± 149 mg/L, P = 0.040) and higher V (24.4 ± 6.4 versus 19.0 ± 3.1 L, P = 0.010). The differences in AUC∞ were not significant (1275 ± 477 versus 1515 ± 352 mg·h/L, P = 0.16). The peak concentrations in subcutaneous tissue were reached rapidly and declined in parallel with the plasma concentrations. The drug exposure in tissue was nearly halved in obese compared with non-obese patients (AUC∞ 1052 ± 394 versus 1929 ± 725 mg·h/L, P = 0.0010). The tissue/plasma ratio (AUCISF/AUCplasma) was 0.86 ± 0.32 versus 1.27 ± 0.34 (P = 0.0047).. Whereas the pharmacokinetics of fosfomycin in plasma of surgical patients were only marginally different between obese and non-obese patients, the drug exposure in subcutaneous tissue was significantly lower in the obese patients.

    Topics: Adult; Aged; Anti-Bacterial Agents; Chromatography, Liquid; Female; Fosfomycin; Humans; Male; Middle Aged; Obesity; Plasma; Prospective Studies; Subcutaneous Fat; Tandem Mass Spectrometry

2019

Other Studies

1 other study(ies) available for fosfomycin and Obesity

ArticleYear
Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:6

    The most suitable method for predicting the glomerular filtration rate (GFR) in obesity is currently debated. Therefore, multiple GFR/creatinine clearance prediction methods were applied to (morbidly) obese and nonobese patients ranging from moderate renal impairment to glomerular hyperfiltration and their predictions were rated based on observed fosfomycin pharmacokinetics, as this model drug is exclusively eliminated via glomerular filtration.. The GFR/creatinine clearance predictions via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD; indexed and de-indexed by body surface area) and creatinine clearance via the Cockcroft-Gault formula (CLCR

    Topics: Creatinine; Female; Fosfomycin; Glomerular Filtration Rate; Humans; Male; Obesity; Renal Insufficiency, Chronic

2022